BioSpace News Archive

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”) today announced that data from 14 studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in Philadelphia, Pennsylvania and at the 2023 American College of Rheumatology Convergence (ACR), taking place November 10-15 in San Diego, California.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

AIVITA Biomedical, Inc. announced that chief executive officer Hans S. Keirstead, Ph.D. will moderate a keynote panel and deliver a talk at the World Vaccine Congress Europe, taking place October 16-19 in Barcelona, Spain.

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that three abstracts will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2023 Annual Meeting.

Rhythm Pharmaceuticals, Inc. announced that on October 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 18,295 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 12,530 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 5,765 shares of its common stock.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced upcoming poster presentations at two scientific conferences being held in November 2023.

The award recognises researchers and companies for developing products that have led to significant advancements in improving health and the environment.

Nortech Systems Incorporated (Nasdaq: NSYS) will hold a live conference call and webcast at 4:00 p.m. central time on Wednesday, November 8, 2023, to discuss the company’s third quarter financial results.

Boundless Bio today will present preclinical data on its second ecDNA-directed therapy (ecDTx), BBI-825, as well as present additional research on the intrinsic genomic plasticity of cancer cells enabled by ecDNA at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced topline results from the INTUNE study in patients with idiopathic hypersomnia.